NL-OMON45898
Recruiting
Not Applicable
A phase I/II Study to Evaluate the Safety and Feasibility of Dual-modality imaging using Indium-111-DOTA-labetuzumab-IRDye800CW in patients with Peritoneal Carcinomatosis of Colorectal Origin - The DuMoPEC study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Radboud Universitair Medisch Centrum
- Enrollment
- 29
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Clinical diagnosis of peritoneal carcinomatosis of colorectal origin.
- •Scheduled for cytoreductive surgery and HIPEC.
- •Age over 18 years
- •Signed informed consent
Exclusion Criteria
- •Any medical condition present that in the opinion of the investigator will affect patients\* clinical status.
- •Administration of a radionuclide within 10 physical half\- lives prior to study enrollment
- •Pregnancy or lactation
- •Very high (\>500 ng/ml) serum CEA levels
- •Immunohistochemically proven non\-CEA expressing primary tumor (if analyzed in primary tumor resection specimen)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid ArthritisRheumatoid ArthritisMedDRA version: 20.0Level: HLTClassification code 10039075Term: Rheumatoid arthritis and associated conditionsSystem Organ Class: 100000004870Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2017-001944-36-BGAmgen Inc153
Active, not recruiting
Phase 1
Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid ArthritisRheumatoid ArthritisMedDRA version: 20.0Level: HLTClassification code 10039075Term: Rheumatoid arthritis and associated conditionsSystem Organ Class: 100000004870Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2017-001944-36-PLAmgen Inc153
Active, not recruiting
Phase 1
Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus ErythematosusSystemic Lupus ErythematosusMedDRA version: 21.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2017-002564-40-DEAmgen Inc140
Active, not recruiting
Phase 1
Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid ArthritisRheumatoid ArthritisMedDRA version: 20.0Level: HLTClassification code 10039075Term: Rheumatoid arthritis and associated conditionsSystem Organ Class: 100000004870Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2017-001944-36-ESAmgen Inc36
Active, not recruiting
Phase 1
aEUCTR2019-004883-23-FRAPHP